OBJECTIVES: Choice of prosthesis type in middle-aged patients undergoing aortic valve replacement (AVR) is still debated. The aim of this study is to compare long-term follow-up results in middle-aged patients who underwent isolated AVR with a biological or mechanical prosthesis.
INTRODUCTION
The choice between a biological and mechanical prosthesis in middle-aged patients undergoing aortic valve replacement (AVR) is still debated. While the current guidelines suggest the use of a mechanical prosthesis in patients aged <60 years old undergoing AVR (level of evidence II) [1] , the use of biological prostheses is still growing.
Pros and cons for each prosthesis type have been suggested [2, 3] . For mechanical prostheses, long-term durability has been considered a great advantage over biological prostheses. However, the concerns about the potential bleeding and cerebrovascular events associated with life-long anticoagulation often compel physicians and patients to choose a biological prosthesis. Conversely, biological prostheses have a limited durability, especially in young patients [4] [5] [6] [7] [8] [9] . However, it seems that new biological prostheses may last longer than the old prostheses. Consequently, results of previous trials are not actual anymore [2, 10, 11] . In addition, reoperation does not seem to confer a higher morbidity and mortality risk anymore [12] [13] [14] [15] and transcatheter valve-in-valve replacement may offer a valuable reoperative alternative in the future [16, 17] .
In keeping with the results reported by registries [18, 19] , there has been a tendency at our institution over the last 20 years towards the use of more biological rather mechanical aortic valve prostheses. Therefore, the aim of this study was to look for longterm outcomes in middle-aged patients who underwent aortic AVR with a biological prosthesis and to compare them with the long-term outcomes of propensity score-matched patients who underwent aortic AVR with a mechanical prosthesis.
METHODS

Patients
A retrospective single-centre study of patients aged between 55 and 65 years old receiving isolated AVR with a mechanical or biological prosthesis between January 1996 and January 2008 was performed. Patients undergoing cardiac redo operation, combined valve surgery, replacement of the ascending aorta and coronary artery bypass grafting (CABG) were excluded from the study. Patients receiving a biological prosthesis formed Group A and were 1 : 1 matched through propensity scores to middle-aged patients receiving a mechanical prosthesis, which formed Group B.
Patient records were retrospectively reviewed. Follow-up was carried out by contacting surviving patients at home or their physician by phone and ended on 1 June 2014. Overall, mean followup was 117 ± 51 months (range, 2-216 months). For Group A and B patients, mean follow-up was 106 ± 46 months (range, 2-210 months) and 128 ± 54 months (range, 4-216 months), respectively. The last transthoracic echocardiogram was retrieved by contacting the referring cardiologist, whenever possible.
Descriptions of morbidity and mortality were based on guidelines for reporting morbidity and mortality after cardiac valve surgery [20] .
The institutional ethics committee waived the need for patient consenting to the study.
Surgery and management of anticoagulation
Patients signed an informed consent to AVR, after having before been informed about the advantages or disadvantages of each prosthesis type.
At our institution, the technique for aortic valve prosthesis implant as well as the postoperative patient management did not change during the study period. After median sternotomy or j-shape sternotomy for minimally invasive approach, cardiopulmonary bypass was instituted by cannulating the ascending aorta and the right atrium. After infusion of antegrade cardioplegia and aortotomy, prostheses were implanted using multiple 2-0 U-shaped single stitches reinforced with pledgets. Postoperatively, all patients were treated with unfractionated heparin until removal of chest tubes and warfarin was initiated thereafter.
After hospital discharge, patients with a biological prosthesis were anticoagulated with warfarin with a target international normalized ratio (INR) between 2 and 3 for 2 months. Thereafter, patients received only aspirin, if not otherwise indicated. Patients with a mechanical prosthesis were anticoagulated lifelong with a target INR between 2.5 and 3.5.
Data analysis
Data analysis was performed using SPSS 21.0 (IBM, NY, USA) and the Propensity score matching extension from the SPSS Extension Bundle. Primary end-points were mortality and freedom from structural valve deterioration (SVD), redo AVR, cardiac reoperation of any type, endocarditis, thromboembolic and bleeding events. Categorical and continuous variables were summarized as percentages and means ± standard deviation (SD) or median with interquartile range (IQR), respectively.
The matching between groups was performed through propensity score analysis. Propensity scores were developed based on five covariates in a logistic regression model with AVR with biological prosthesis as the dependent variable. The variables that showed a difference among groups (arterial hypertension) and could have an impact on prosthesis durability or patient survival (smoke history, presence of diabetes mellitus, hyperlipidaemia and male sex) were used as covariates. One to one matching, a nearest neighbour algorithm and a caliper of 0.15 were used for the matching process. Units outside of common support were discarded for both control and treated patients.
After matching, the independent-samples Student's t-test or the non-parametric Mann-Whitney U-test and the χ 2 or Fisher's exact tests were used for group comparisons of continuous and categorical variables, respectively. Two-tailed P-values ≤0.05 were considered significant.
Survival estimates along with freedom from SVD, redo AVR, cardiac reoperation of any type, endocarditis, thromboembolic and bleeding events were calculated by the product-limit method of Kaplan-Meier. Differences among groups were quantified using the log-rank test.
RESULTS
Patient characteristics
Between January 1996 and January 2008, among the patients who received aortic valve prosthesis at our institution, 183 patients aged 55-65 years old underwent isolated AVR and fulfilled the selection criteria to enter the study. Sixty-one (33%) patients underwent AVR with a biological prosthesis and the remaining 122 (66%) patients with a mechanical prosthesis. After 1 : 1 matching through propensity scores, 60 patients with a biological prosthesis formed Group A and 60 patients with a mechanical prosthesis formed Group B (Fig. 1) .
Pre-, intra-and postoperative patient characteristics did not differ between groups, except for longer cardiopulmonary bypass and cross-clamp times in Group B patients (Tables 1 and 2 ). During the study period, four types of biological prostheses had been used at our institution. Instead, only one type of mechanical prosthesis had been used throughout the study period (Table 2) .
Among matched patients, the percentage of biological prostheses for each study year was 25% in 1996, 8% in 1997, 33% in 
Survival
Two (3%) Group A patients died in hospital (Table 2) . One patient with underlying liver cirrhosis died of sepsis and multiorgan failure 2 weeks after uncomplicated AVR. The other patient died of unexplained asystolic arrest 2 weeks after AVR. There was no hospital mortality in Group B patients.
Fourteen (24%) Group A and 22 Group B (37%) patients died after hospital discharge. Among these patients, cardiac-related deaths were reported in 7 (50%) Group A patients vs 12 (55%) Group B patients (P = 0.79). Survival at 10 and 15 years was similar among Group A and B patients (P = 0.95). Survival estimates and the corresponding plots for each patient group are reported in Table 3 and Fig. 2 , respectively.
Structural valve deterioration and non-structural valve dysfunction
Eight (14%) Group A patients showed SVD at transthoracic echocardiography (prosthesis regurgitation, n = 1; stenosis, n = 4; and mixed stenosis/regurgitation, n = 3). If prosthesis type is considered, SVD was detected in 4 patients (10%) with CE Perimount (Edwards LifeSciences, Irvine, CA, USA) prosthesis, in 2 (28%) patients with a Sorin Mitroflow prosthesis (Sorin Group, Milan, Italy), in 1 (8%) patient with a Medtronic Mosaic (Medtronic, Inc., Minneapolis, MN, USA) prosthesis and in the only 1 patient with a SJM Toronto SPV (St Jude Medical, St Paul, MN, USA) stentless prosthesis. Two (3%) Group B patients presented reduced movement of prosthesis occluders with severe stenosis and regurgitation at echocardiography, due to the presence of thrombus and an immobile occluder in 1 patient and due to only occluder immobility in the other. Incidence of SVD at 10 and 15 years was higher for Group A than B patients (P = 0.003). Freedom estimates from SVD and the corresponding plots for each patient group are reported in Table 3 and Fig. 3 , respectively. In addition, 4 Group A (7%) patients showed a non-structural valve dysfunction (non-SVD), due to endocarditis (n = 3) or patient-prosthesis mismatch (n = 1). Only 1 Group B (2%) patient showed non-SVD due to endocarditis.
Reoperation
Nine Group A (16%) patients versus 8 Group B (13%) patients underwent a cardiac reoperation of any type.
Seven Group A (12%) patients underwent redo AVR for SVD (n = 4) or endocarditis (n = 3), 6 of whom received a biological prosthesis again. Three Group B patients underwent redo AVR for SVD (n = 2) or endocarditis (n = 1), and all received a biological prosthesis. SVD was confirmed intraoperatively in all patients. Only 1 Group B patients showed a prolonged postoperative course after redo AVR. Three patients required pacemaker implant. Incidence of redo AVR for any reason at 10 and 15 years was higher in Group A than B patients (P = 0.04). Conversely, freedom from redo AVR due to SVD was similar among groups (P = 0.11). Freedom estimates and the corresponding plots for each patient group are given in Table 3 and Fig. 4 , respectively.
The remaining 2 Group A patients underwent biological mitral valve replacement and the remaining 5 Group B patients underwent CABG (n = 3) or mitral valve replacement (n = 2).
Overall, freedom from cardiac reoperation of any type was similar between patient groups (P = 0.28). Freedom estimates and the corresponding plots for each patient group are reported in Table 3 and Fig. 5A , respectively. 
Endocarditis
Five Group A (9%) patients presented an episode of endocarditis, which directly involved the aortic prosthesis in 3 patients. These 3 patients required redo AVR. In Group B, only 1 patient showed endocarditis, which involved the aortic prosthesis and required redo AVR. In none of these redo cases, infective endocarditis had been the initial indication for AVR. Group A patients showed a slightly higher incidence of endocarditis at 10 and 15 years (P = 0.05). Freedom estimates and the corresponding plots for each patient group are reported in Table 3 and Fig. 5B , respectively.
Cerebrovascular and bleeding events
At end follow-up, 14 Group A (24%) patients were still anticoagulated with warfarin, due to atrial fibrillation in 10 cases.
Five Group A (9%) patients showed a cerebrovascular event (stroke, n = 3; transitory ischaemic attack, n = 2). Four patients recovered completely from the cerebral insult. One Group B patient suffered from a haemorrhagic stroke 7 years after mechanical AVR but then recovered fully. Group A patients showed a higher incidence of cerebrovascular events at 10 and 15 years (P = 0.03). Freedom estimates and the corresponding plots for each patient group are presented in Table 3 and Fig. 5C , respectively.
Four Group A (7%) patients (gastrointestinal bleeding, n = 1; intracerebral bleeding, n = 1; haemoptysis, n = 1; recurrent epistaxis, n = 1) and 6 Group B (10%) patients (gastrointestinal bleeding, n = 4; haemorrhagic pericardial effusion, n = 1; and recurrent epistaxis, n = 1) showed at least one bleeding event. Among Group A patients, 2 patients were anticoagulated with warfarin and the other 2 were only treated with aspirin. There was no difference among groups regarding the incidence of bleeding events at 10 and 15 years (P = 0.94). Freedom estimates and the corresponding plots for each patient group are reported in Table 3 and Fig. 5D , respectively.
DISCUSSION
This retrospective observational study compared long-term results among propensity score-matched middle-aged patients undergoing AVR with a biological or mechanical prosthesis, and Freedom from endocarditis (B) and cerebrovascular events (C) was higher in Group B than A patients (P = 0.05 and P = 0.03, respectively). Instead, freedom from cardiac reoperation of any type (A) and bleeding events (D) was similar in Group A and B patients (P = 0.28 and P = 0.98, respectively). Patients at risk are reported above the X-axis.
showed that there was no difference in long-term survival, incidence of bleeding accidents and cardiac redo operations for any reason among groups. However, Group A patients showed a higher rate of prosthesis SVD, redo AVR, cerebrovascular events and endocarditis.
This study focuses on one of the still most debated conundrums in cardiac surgery: which kind of prosthesis is best suited to and should be implanted in patients younger than 65 years undergoing AVR. In order to avoid a confounding effect on survival, patients with associated coronary artery disease undergoing CABG or with combined valve disease and patients undergoing cardiac redo operation were excluded from the present analysis. In addition, in order to compensate the lack of randomization, a match among patients through propensity scores was performed. The study population was limited to patients aged between 55 and 65 years old and showed a follow-up up to 18 years.
This age group represents the patient cohort where the choice between a biological and mechanical prosthesis is most controversial. Recently, there has been a growing tendency to favouring implantation of a biological prosthesis in these patients, usually due to surgeon choice or to fulfil patient preference. Patient preference seems to play an ever-growing important role in decision making, since patients come to surgery already knowing the pros and cons of a mechanical or biological prosthesis and which kind of prosthesis better suits to them. In addition, the most recent European Society of Cardiology (ESC)/European Association for Cardio-thoracic Surgery (EACTS) guidelines on management of valvular heart disease have shifted the previous cut-off of 65 years for implanting a mechanical valve to the actual cut-off of 60 years [1, 21] .
However, many studies, both randomized and observational, have reported better survival and freedom from valve-related morbidity in middle-aged patients undergoing AVR with a mechanical than a biological prosthesis [4] [5] [6] [7] [8] [9] 22] . Brown et al. showed better survival at 5 and 10 years in patients undergoing mechanical versus biological AVR (87 and 68% for mechanical prosthesis vs 72 and 50% for biological prosthesis, respectively) [6] . Similarly, but with a shorter follow-up (33 ± 24 months), Weber et al. reported an inferior survival in patients undergoing biological versus mechanical AVR (90.3 vs 98% at 30 months follow-up, respectively) [8] . Badwahr et al. also showed a trend towards better survival in patients with a mechanical AVR, with a mortality benefit over biological prosthesis as early as 7.5 years after AVR [9] . In comparison to these studies, our study population was smaller, since it included only patients aged 55-65 years, presented a longer follow-up and showed no difference in survival among groups. The lack of difference in survival was still present up to 15 years after initial AVR.
The most important concern associated with biological prosthesis is prosthesis durability. SVD has been described in every available biological aortic prosthesis [3] . New prosthesis designs and tissue fixation procedures may reduce further SVD rate in the future. In the present study, four models of biological prosthesis were implanted, with an overall freedom from SVD amounting to 81% at 10 years and 64% at 15 years. Only the Medtronic Mosaic (Medtronic, Inc.) and the CE Perimount (Edwards LifeSciences) bioprostheses had undergone an anticalcification treatment at that time. However, better freedom from SVD has been described for the single prosthesis types. A 10-and 15-year actuarial freedom from SVD up to 98 and 86%, respectively, has been recently described for the Medtronic Mosaic (Medtronic, Inc.) prosthesis. Actual freedom from SVD was even better with rates up to 98.5 and 95.1% at 10 and 15 years, respectively. However, after age stratification, SVD rates were worse in patients younger than 70 years [23] . Similar results were reported for the Sorin Mitroflow (Sorin Group) bioprosthesis, where overall 20-year freedom from SVD was 62.3%. However, also in this study, actuarial freedom from reoperation for SVD at 20 years was lower in patients aged between 65 and 70 years [24] . For the CE Perimount (Edwards LifeSciences) bioprosthesis, the freedom rate from prosthetic valve dysfunction was 84 and 57% at 10 and 15 years, respectively [25] . The reason why younger patients develop bioprosthesis SVD more frequently than older patients is still debated. It has been postulated that an autoimmunological reaction could initiate SVD in these patients [14] . In keeping with the results of the previous cited studies as well as ours, it can be concluded that implantation of a biological prosthesis should be avoided in younger patients. However, many patients aged between 55 and 65 years may not outlive their prosthesis due to additional comorbidities that impair live expectancy. Moreover, even mechanical prostheses show SVD. In the present study, one patient showed immobility of an occluder without the presence of thrombus or pannus. Finally, many patients undergoing AVR are aware of the risk of developing SVD in the future, but in spite of this they choose a biological prosthesis.
Need for redo AVR usually follows the development of SVD. The previously cited studies reported freedom from redo AVR for SVD up to 99.4 and 98.4% at 10 and 15 years respectively, for the Medtronic Mosaic (Medtronic, Inc.,) prosthesis [23] ; 71.8 and 84.8% at 20 years in patients 65 years or older and 70 years or older respectively, for the Sorin Mitroflow (Sorin Group) prosthesis [24] ; and 79 and 58% at 10 and 15 years respectively, for the CE Perimount (Edwards LifeSciences) bioprosthesis [25] . Again, rates of redo AVR for SVD were higher in young patients [23] [24] [25] . In our study, freedom from redo AVR up to 73% at 15 years was reported. However, also patients undergoing redo AVR for non-SVD were included, with only 4 patients showing SVD. If only patients undergoing AVR for SVD were considered, there was even no difference among groups at long-term follow-up. Moreover, freedom from cardiac redo of any type was also similar among groups. Consequently, AVR with a biological prosthesis should not be refused to young patients solely on the basis of a potential risk of future redo AVR. Patients with a mechanical prosthesis do also have a risk of redo AVR, let aside from cardiac redos of any type. In addition, postoperative results of redo AVR have been encouraging and improving during the last years. In-hospital mortality rates between 3 and 6% have been recently reported [12] [13] [14] [15] . It has also been speculated that transcatheter valve-in-valve techniques may further reduce mortality and morbidity after redo AVR in the future. However, results are still preliminary and the open surgical technique should still be considered the gold standard for redo AVR [16, 17] . Finally, indication for redo AVR may occur urgently or even as an emergence due to leaflet tear, requiring an urgent redo AVR [14] at an increased risk.
In the present study, incidence of endocarditis was higher in patients with a biological than mechanical prosthesis. However, this seems a fortuitous finding, since many studies have not shown a difference in freedom from endocarditis among patients with a biological or mechanical prosthesis [5] [6] [7] [8] [9] 22] . Surely, further study, enrolling a larger patient population, is required, including stratification for age.
An important reason, which usually moves patients to choose a biological prosthesis, is to avoid lifelong anticoagulation and the potential complications associated to it, such as cerebrovascular and bleeding accidents. Some recent comparative studies have shown no difference between patients undergoing AVR with a biological or mechanical prosthesis regarding freedom from thromboembolic and bleeding events. In a recent prospective randomized trial, Stassano et al. showed no differences in the linearized rate of thromboembolism, bleeding, endocarditis and major adverse prosthesis-related events between patients with a mechanical or biological prosthesis [7] . Badhawar et al. also showed that optimal freedom from bleeding and thromboembolic events in patients with a mechanical prosthesis could be achieved by targeting lower INR thresholds, between 2 and 3 instead of 2.5 and 3.5 [9] . Weber et al. demonstrated that patients with a biological prosthesis had even a survival benefit if they were anticoagulated at follow-up [8] . In addition, the choice of a biological prosthesis at the time of surgery does not exclude the future need of anticoagulation. Indeed, in our case series, 14 Group A patients were still anticoagulated at end follow-up, mostly due to atrial fibrillation. In keeping with the previous studies, we showed no difference among groups regarding incidence of bleeding accidents. In contrast, a higher incidence of cerebrovascular accidents was observed in patients with a biological prosthesis. Among the 5 Group A patients who suffered from a cerebrovascular accident, 3 patients (2 patients with TIAs) showed also SVD. It has been suggested that prosthesis developing SVD could shed calcific debris, potentially inducing cerebrovascular accidents [10] .
STUDY LIMITATIONS
The retrospective nature of this analysis introduced inherent limitations, although the lack of randomization was partly compensated by the propensity score matching. In fact, over the study period, there could have been some selection criteria, which could have favoured the implantation of one prosthesis type instead of the other, such as patient wish, surgeon preference, patient life expectancy and high risk for SVD. Since these criteria could not be retrospectively quantified and categorized by continuous and categorical variables, they could not be used for the propensity score analysis. Randomization surely is more helpful in considering these potential confounding factors.
Echocardiographic data such as prosthesis gradients and valve areas were not reported, since they were not found in most of the reports we retrieved from cardiologists.
Quality of life after biological or mechanical AVR was not investigated, since it is more properly tested prospectively than retrospectively.
In comparison to previously published case series, our study population was quite small. Since a 1 : 1 matching between cases (Group A) and controls (Group B) was performed and Group A included 61 patients, 60 Group B patients were matched, yielding a study population of only 120 patients. However, patients with coronary artery disease, combined valve disease or undergoing cardiac redo were excluded in order to avoid the impact of associated disease on patient prognosis. In addition, due to the small study population, a multivariate analysis to look for risk factors of end-points was not performed.
CONCLUSIONS
Middle-aged patients undergoing biological AVR showed survival and incidences of redo AVR for SVD, cardiac reoperation of any type and bleeding events similar to patients undergoing mechanical AVR. However, incidences of SVD, redo AVR for any reason, endocarditis and cerebrovascular accidents were higher in patients with biological AVR than those with mechanical AVR. Thus, a biological prosthesis may be better suited for those middle-age patients who will not outlive prosthesis durability. In candidates with an uncompromised long-term prognosis based on absent disease in other organ systems, we would now recommend implantation of a mechanical prosthesis. If the 55-60 years old patient definitely prefers a biological substitute, we would do so only after discussing its long-term durability and expected valve-related morbidity.
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